Turning Point Brands Q3 2026 slides: Modern Oral surges, margins dip
Turning Point Brands (TPB) reported Q3 2026 revenue of $151.1M (+27% YoY) but adjusted EBITDA fell 41% to $18.4M due to investments in its Modern Oral nicotine pouch business. Modern Oral revenue surged 102.9% YoY to $74.4M, now 49% of total sales. Shares fell 7.32% post-earnings, trading at $64.01. The company reaffirmed FY 2026 guidance, projecting Modern Oral net sales of $260-270M and adjusted EBITDA of $70-80M.
How this was made
The 30-second read
Why it matters
Earnings miss on profitability may trigger further sell‑offs, but the strong top‑line growth and strategic investments could support a rebound.
Market read
The earnings release provides fresh guidance and performance metrics that directly affect TPB's stock price and the broader nicotine product sector.
What to watch
Potential future margin expansion as Modern Oral scales to target 70% margins and upcoming U.S. manufacturing.
Background
Turning Point Brands is transitioning from traditional tobacco to modern oral nicotine products, investing heavily in sales and manufacturing.
Ticker impact
Q3 2026 earnings release showing 27% revenue growth but 41% EBITDA decline and guidance range, causing a 7.3% share drop.
likely further pressure as investors digest profitability decline
Earnings miss on EBITDA and wide guidance range typically trigger sell pressure, especially after a 7% drop.
Market effects
Highlights growth in the nicotine pouch segment, may boost peer valuations in tobacco/alternative nicotine space.
U.S. consumer discretionary and tobacco stocks could see short-term volatility.
Limited to U.S. market; no immediate global macro effect.
Counterpoint
Investors could view the revenue beat and aggressive growth as a buying opportunity despite short-term margin pain.
Key entities
- companyTurning Point Brands
NYSE‑listed tobacco and nicotine products company.
- executiveDavid Glazek
CEO providing commentary on organic growth strategy.




